pTNM System in Non Small Cell Lung Carcinoma

Heriawaty Hidayat\(^1\), Sutjahjo Endaro\(^1\), Ruth E Sembiring\(^1\), Aziza Icksan\(^2\), Elsina Syahrudin\(^3\), Agung Wibawanto\(^4\)
\(^1\)SMF Patologi Anatomi RS. Persahabatan, \(^2\)SMF Radiologi RS. Persahabatan, \(^3\)Departemen Pulmonologi FKUI / RS Persahabatan, \(^4\)SMF Bedah Toraks RS Persahabatan.

ABSTRAK

Prognosis karsinoma paru berhubungan dengan berbagai macam faktor, antara lain: usia, jenis kelamin, ukuran tumor, staging, jenis sel dan derajat diferensiasi, invasi kepembuluh darah, dinding dada, efusi pleura, adanya jaringan ikat, keterlibatan KGB, reaksi radang, ploid DNA dan ekspresi onkogen.

Adanya hubungan langsung antara staging klinik dan angka ketahanan hidup sudah dibuktikan, terutama untuk karsinoma bukan sel kecil. Staging TNM merupakan parameter prognostik terpenting dan merancang terapi pada karsinoma paru, seperti pada kebanyakan tumor lainnya.

Semua kasus karsinoma paru sebaiknya ditangani oleh tim kanker paru multidisiplin. Jika ditemukan perbedaan bernakhtah inti klinis dan radiologik, sebaiknya diagnosis sediaan patologis jaringan paru direview ulang, jika memungkinkan oleh ahli patologi kedua yang berpengalaman dalam kanker paru.

Prosedur pemeriksaan imunohistokimia harus dilakukan bila diagnosis histopatologik tidak pasti.

Kata Kunci: pTNM, NSCLC, kanker paru-paru

ABSTRACT

The prognosis of lung carcinoma has been related to a large number of factors, such as: age, sex, location, tumor size, stage, cell type and degree of differentiation, blood vessel invasion, chest wall invasion, pleural effusion, presence of a scar, lymph node involvement, inflammatory reaction, DNA ploidy and oncogene expression.

A direct relationship is evident between clinical stage and survival rates, particularly for non small cell carcinoma (NSCLC). Actually, TNM stage is regarded by most as the single most important prognostic parameter and treatment planning in lung carcinoma, as it is in many other tumors throughout the body.

All lung cancer cases should be reviewed by Lung Cancer multidisciplinary team. If there is a significant discrepancy between the clinical / radiological findings the pathological material from diagnostic lung specimens should be reviewed, if possible by a second pathologist with an interest in lung cancer.

Immunohistochemical procedures must be performed when histopathological diagnostic was uncertain.

Key Worlds: pTNM, NSCLC, lung cancer

INTRODUCTION

Once the TNM status is determined, a clinical stage is assigned. It is on the basis of clinical stage that operability is assessed and on which considerable prognostic information rests.\(^1\) Individuals having tumour with clinical stage III A or lower tumor may be candidates for resection whereas those with clinical stage III B and IV are not\(^1\). The role of surgery in stage III A lung carcinoma is controversial and not unanimously advocated.\(^1\)

The staging of cancer is important to: \(^2\)
1. To aid the clinician in the planning of treatment.
2. To give some indication of prognosis.

ALAMAT KORESPONDENSI

dr. Heriawaty Hidayat, Sp.PA
Departemen Patologi Anatomi, RS Persahabatan Jl. Persahabatan Raya Jakarta Timur

2008, Indonesian Journal of Cancer 4, 135 - 137
3. To assist in evaluation of the results of treatment.
4. To facilitate the exchange of information between treatment centres.
5. To contribute to the continuing investigation of human cancer.

The clinical stage (cTNM) assignment is based on all information obtained before treatment is very important in making a decision for the most effective treatment. Surgical – pathological staging (pTNM), based on pathological examination of resected specimen, is useful for defining the extent of the primary tumor and regional lymph node metastasis. The clinical stage is essential to select and evaluate therapy, and completed with the pathological stage provides the most precise data to estimate prognosis and calculate end results. In multimodality therapy programs, retreatment staging (rTNM evaluation of disease extent following initial or induction therapies) may be useful for assigning subsequent treatment steps, as well as for evaluating the end results.

CASE REPORT

A 57 year old male came to Persahabatan Hospital with complain of dyspnoe, cough and dysphagia. The chest CT showed clinical stage T3N0M0.

TTNA guided CT was performed from the mass. Cytology confirmed as adenocarcinoma. Surgical staging was T4N2M0. Histopathological evaluation of resection specimens was conducted and the result was still in.

Differential diagnosis of large cell carcinoma neuroendocrine tumor and adenocarcinoma or mixed tumors. The immunohistochemistry was performed in this tumor and the results was consistent with adenocarcinoma. Lymph node stations number 11 was positive histologically, the pTNM being T4N1M0.

Histopathological finding showed neuroendocrine features such as; Rosette – like structures, focal palisading, central necrosis and organoid pattern.

GUIDELINES FOR THE EXAMINATION AND REPORTING OF LUNG CANCER SPECIMENS9 (see appendix)

SUMMARY

The preoperative clinical staging (cTNM) in this case was T3N0M0, finding from chest CT. The surgical staging was T4N2M0 because the tumor has infiltrated to the pulmonary arteri, node station 7, 9 and 11 were enlarged. This discrepancy maybe caused by time delayed interval during the chests CT to surgical treatment (two months).5 The pathological staging (pTNM) was pT4N1M0, because only node station 11 was histologically positive.6 The positive lymph node diameter were over 1 cm and the other negative lymph node were less than 1 cm.

Histopathological finding differential diagnosis of the tumor were large cell carcinoma neuroendocrine and adenocarcinoma because the tumor showed varying degrees of neuroendocrine morphologic features by light microscopy including organoid nesting, focal palisading, rossete – like structures and central necrosis.7 Large cell neuroendocrine carcinoma & combined large cell neuroendocrine carcinoma have a worser prognosis, stage distribution are often stage III – IV at diagnosis.8,9 Immunohistochemical procedures and referral to the other specialist opinion was value in this case because the rarity type of the tumour and the tumor showed neuroendocrine differentiation. Confirmation of neuroendocrine differentiation is required using immunohistochemical markers such as chromogranin, synaptophysin and NCAM (CD56).10

The immunohistochemistry was performed in this tumour and the results was negative for neurone specific enolase and chromogranin but positive for cytokeratine and CEA. The definitive histopathological diagnosis was adenocarcinoma.
REFERENCES


APPENDIX

Guidelines for the examination and reporting of lung cancer specimens

1. Specimen Types
   Diagnostic:
   Bronchial biopsy
   Bronchial cytology (brushings, washings, tranbronchial needle aspiration)
   Needle core biopsy

   Therapeutic:
   Segmentectomy
   Lobectomy
   Sleeve resection
   Pneumonectomy
   Pleurectomy
   Pleuropneumonectomy

2. Minimum dataset for reporting
   Diagnostic specimens: tumour type
   Therapeutic resections:
   - Specimen type
   - Specimen dimensions
   - Location of tumour
     - Central (main / segmental bronchus)
     - < 2 cm / ≥ 2 cm from carina
   - Peripheral (parenchymal / pleural)
   - Tumour size
   - Extent of atelectasis or obstructive pneumonitis
   - Tumour type (WHO International Histological Classification of Tumours)
   - Tumour grade (WHO carcinoma grade system)
   - Local invasion (pleura, chest wall, mediastinal structure, etc)
   - Lymph node spread (by node station group)
   - Resection margins (bronchial, mediastinal, vascular and chest wall)
   - Other relevant pathology
   - pTNM staging system (according to vTNM classification of malignant tumours)

   A direct relationship is evident between clinical stage and survival rates, particularly for non small cell lung carcinoma (NSCLC) but is generally not utilized in small cell lung carcinoma (SCLC). Pathologic staging (pTNM) is based on the pathologic evaluation of sampled tissues according to the TNM system.

3. Use of ancillary laboratory techniques
   Immunohistochemical procedures which may be of value include the following:
   - Neuroendocrine differentiation
   - Primary or metastatic carcinoma
   - Adenocarcinoma v mesothelioma
   - Small cell carcinoma v lymphoma

4. Referral for review or specialist opinion
   Situation when review is important include when there is a significant discrepancy with the clinical/radiological findings, or when the original pathologist expressed diagnostic uncertainty or when a rare type of tumour is diagnosed.

2008, Indonesian Journal of Cancer 4, 135-137